Bibliography
- VOGELSTEIN B, LANE D, LEVINE AJ:Surfing the p53 network. Nature (2000) 408:307–310.
- CHENE P: Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nat. Rev Cancer (2003) 3:102–109.
- ISSAEVA N, BOZKO P, ENGE M et al:Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat. Med. (2004) 12:1321–1328.
- RIVERA MI, STINSON SF, VISTICA JTet al.: Selective toxicity of the tricyclic thiophene NSC 652287 in renal carcinoma cell lines. Biochern. Phannacol. (1999) 57:1283–1295.
- NIEVES-NEIRA W, RIVERA MI, KOHLHAGEN G et al.: DNA protein cross-links produced by NSC 652287, a novel thiophene derivative active against human renal cancer cells. J. Pharmacol Exp. Ther. (1999) 56:478–484.
- ZHAO J, WANG M, CHEN J et al.: Theinitial evaluation of non-peptidic small-molecule HDM2 inhibitors based on p53-HDM2 complex structure. Cancer Lett. (2002) 183:69–77.
- LAI Z, YANG T, KIM YB et al: Differentiation of Hdm2-mediated p53 ubiquitination and Hdm2 autoubiquitination activity by small molecular weight inhibitors. Proc. Natl. Acad. Sci. (2002) 99:14734–14739.
- VASSILEV LT, VU BT, GRAVES B et al:In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science (2004) 303:844–848.